As regulatory momentum accelerates around new approach methodologies (NAMs), toxicology and safety teams are under growing pressure to adopt new technologies without increasing risk.
This webinar examines the scientific and regulatory forces reshaping safety assessment and what they mean for real-world decision making today. Gain perspective on how leading organizations are navigating this transition and what differentiates NAM platforms that can withstand regulatory scrutiny.
Through real-world context and industry examples, the session highlights how a regulatory-aligned approach such as Maestro MEA can support confident, future-ready safety strategies while reducing uncertainty during adoption.
About the presenter:
Mike Clements, PhD
SVP Scientific Partnerships & Strategy
Dr. Mike Clements is the Senior Vice President for Scientific Partnerships & Strategy at Axion BioSystems, where he is focused on initiatives advancing the use of human stem cell-derived models in drug discovery and toxicology. He earned his PhD in neuropharmacology from the University of Oxford, with postdoctoral training in the UK and the US.
In 2014, Dr. Clements published the first study utilizing the Maestro multielectrode array (MEA) system with stem cell-derived cardiomyocytes, demonstrating their potential as predictive tools for preclinical cardiac safety screening, which would later help inform the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. He was also the editor of Stem Cell-Derived Models in Toxicology, a resource that reviewed next-generation in vitro toxicology platforms. Dr. Clements previously served as president of the Stem Cells Specialty Section of the Society of Toxicology.
